Therapies for neurological disease in the mucopolysaccharidoses

Current Gene Therapy

Volumn 11, Issue 2, 2011, Pages 132-143

  Anson, Donald S ^a,b   McIntyre, Chantelle ^a,b   Byers, Sharon ^a,b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Disease; Glycosaminoglycan; Mucopolysaccharidosis; Neurological; Storage; Therapy

Indexed keywords

ACETYLGLUCOSAMINIDASE; BETA GLUCURONIDASE; GAG PROTEIN; GALSULFASE; GENISTEIN; GLUCOSYLTRANSFERASE; IDURONATE 2 SULPHATASE; IMMUNOSUPPRESSIVE AGENT; LARONIDASE; LEVO IDURONIDASE; MANNITOL; MANNOSE 6 PHOSPHATE; MIGLUSTAT; RECOMBINANT ENZYME; RECOMBINANT SULPHAMIDASE; RHODAMINE B; SMALL INTERFERING RNA; SULFATASE; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD BRAIN BARRIER; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE TARGETING; GENE VECTOR; HUMAN; HURLER SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; MUCOPOLYSACCHARIDOSIS; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; REVIEW; RNA INTERFERENCE; SPINAL CORD COMPRESSION; THERAPY EFFECT; ANIMAL; GENE THERAPY; LYSOSOMAL STORAGE DISEASES; MUCOPOLYSACCHARIDOSES; NERVOUS SYSTEM DISEASES; PROCEDURES;

ANIMALS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HUMANS; LYSOSOMAL STORAGE DISEASES; MUCOPOLYSACCHARIDOSES; NERVOUS SYSTEM DISEASES; GENETIC THERAPY;

EID: 79953016563     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652311794940791     Document Type: Review

References (91)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In The Metabolic Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (eds). McGraw-Hill, New York, 1995; 2465-2494.
2. Meikle PJ, Hopwood JJ, Clague AE and Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-254.
3. Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child 1993; 69: 403-406.
4. Hille-Rehfeld A. Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochim Biophys Acta 1995; 1241: 177-194.
5. Prasad VK and Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Sem Hem 2010; 47: 59-69.
6. Soulas C, Donahue RE, Dunbar CE, et al. Genetically modified CD34+ hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates. Am J Pathol 2009; 174: 1808-1817.
7. Vallieres L, Sawchenko PE. Bone marrow-derived cells that populate the adult mouse brain preserve their hematopoietic identity. J Neurosci 2003; 23: 5197-5207.
8. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003; 361: 1608-1613.
9. Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007; 67: 2697-2716.
10. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. Substrate deprivation therapy: a new hope for patients suffering forms of inherited lysosomal storage diseases. J Appl Genet 2007; 48: 383-388.
11. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-1485.
12. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6: 765-772.
13. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of lowdose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179: 1022-1028.
14. Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res 2008; 69: 166-179.
15. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobol Dis 2010; 37: 13-25.
16. Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain-barrier. Proc Natl Acad Sci USA 2004; 101: 12658-12663.
17. Schlageter KE, Molnar P, Lapin GD, et al. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc Res 1999; 58: 312-328.
18. Gliddon BL, Hopwood JJ. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr Res 2004; 56: 65-72.
19. Sferra TJ, Backstrom K, Wang C, Rennard R, Miller M, Hu Y. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 2004; 10: 478-491.
20. McIntyre C, Derrick Roberts AL, Ranieri E, Clements PR, Byers S, Anson DS. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab 2008; 93: 411-48.
21. Bielicki J, McIntyre C, Anson DS. Comparison of Ventricular and Intravenous Lentiviral-Mediated Gene Therapy for Murine MPS VII. Mol Gen Met 2010; 101(4): 370-382.
22. McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and CNS pathology by lentiviral mediated gene transfer. J Gene Med 2010; 12: 717-728.
23. Ma X, Liu Y, Tittiger M, et al. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 2007; 15: 889-902.
24. Herati RS, Ma X, Tittiger M, et al. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med 2008; 10: 972-982.
25. Cardone M, Polito VA, Pepe S, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet 2006; 15: 1225-1236.
26. Jung SC, Park ES, Choi EN, Kim CH, Kim SJ, Jin DK. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy. Mol Cells 2010; 30: 13-18.
27. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci USA 2007; 104: 7594-7599.
28. Ponder KP, Wang B, Wang P, et al. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol Ther 2006; 14: 5-13.
29. Lutzko C, Kruth S, Abrams-Ogg AC, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 1999; 93: 1895-1905.
30. Zheng Y, Rozengurt N, Ryazantsev S, Kohn DB, Satake N, Neufeld EF. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab 2003; 79: 233-244.
31. Zheng Y, Ryazantsev S, Ohmi K, et al. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB. Mol Genet Metab 2004; 82: 286-295.
32. Wang D, Zhang W, Kalfa TA, et al. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci USA 2009; 106: 19958-19963.
33. Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010; 116(24): 5130-5139.
34. Ferguson C, Larochelle A, Dunbar CE. Hematopoietic stem cell gene therapy: dead or alive? Trends Biotechnol 2005; 23: 589-597.
35. Larochelle A, Choi U, Shou Y, et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 2009; 119: 1952-1963.
36. Hall SL, Lau K-HW, Chen S-T, et al. An improved mouse Sca1+ cell-based bone marrow transplantation model for use in gene- and cell-based therapeutic studies. Acta Haemat 2007; 117: 24-33.
37. Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect 2009; 22: 185-196.
38. Gerull S, Beard BC, Peterson LJ, Neff T, Kiem HP. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 2007; 18: 451-456.
39. Ginn SL, Liao SH, Dane AP, et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 2010; 18: 965-976.
40. McCarty DM, DiRosario J, Gulaid K, Muenzer J, Fu H. Mannitolfacilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009; 16: 1340-1352.
41. Belichenko PV, Dickson PI, Passage M, Jungles S, Mobley WC, Kakkis ED. Penetration, diffusion, and uptake of recombinant human alpha-L-iduronidase after intraventricular injection into the rat brain. Mol Genet Metab 2005; 86: 141-149.
42. Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004; 83: 163-174.
43. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91: 61-68.
44. Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet 2008; 146A: 2538-2544.
45. Muñoz-Rojas MV, Horovitz DD, Jardim LB, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4- sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 2010; 99: 346-350.
46. Hemsley KM, Beard H, King BM, Hopwood JJ. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 2008; 7: 740-753.
47. Hemsley KM, Norman EJ, Crawley AC, et al. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study. Mol Genet Metab 2009; 98: 383-392.
48. Stein CS, Ghodsi A, Derksen T, Davidson BL. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 1999; 73: 3424-3429.
49. Ghodsi A, Stein C, Derksen T, Yang G, Anderson RD, Davidson BL. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther 1998; 9: 2331-2340.
50. Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 1999; 160: 17-27.
51. Sferra TJ, Qu G, McNeely D, et al. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther 2000; 11: 507-519.
52. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1: 63-70.
53. Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther 2000; 11: 1139-1150.
54. Frisella WA, O'Connor LH, Vogler CA, et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther 2001; 3: 351-358.
55. Brooks AI, Stein CS, Hughes SM, et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virusbased vectors. Proc Natl Acad Sci USA 2002; 99: 6216-6221.
56. Liu G, Chen YH, He X, et al. Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol Ther 2007; 15: 242-247.
57. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007; 27: 9928-9940.
58. Vite CH, Passini MA, Haskins ME, Wolfe JH. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 2003; 10: 1874-1881.
59. Desmaris N, Verot L, Puech JP, Caillaud C, Vanier MT, Heard JM. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 2004; 56: 68-76.
60. Ciron C, Desmaris N, Colle MA, et al. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 2006; 60: 204-213.
61. Haskins ME. Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr 2007; 96: 56-62.
62. Ciron C, Cressant A, Roux F, et al. Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 2009; 20: 350-360.
63. Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005; 25: 9321-9327.
64. Davidson BL, Stein CS, Heth JA, et al. Recombinant adenoassociated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97: 3428-3432.
65. Watson G, Bastacky J, Belichenko P, et al. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 2006; 13: 917-95.
66. Fraldi A, Hemsley K, Crawley A, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAVmediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 2007; 16: 2693-202.
67. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virusmediated gene delivery. Mol Ther 2002; 5: 42-4.
68. Cressant A, Desmaris N, Verot L, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 2004; 24: 10229-10239.
69. Di Domenico C, Villani GR, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A 2009; 149A: 1209-1218.
70. Fu H, DiRosario J, Kang L, Muenzer J, McCarty DM. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med 2010; 12: 624-633.
71. Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007; 14: 1065-1077.
72. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105.
73. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463-474.
74. Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010; 18: 873-880.
75. Buchet D, Serguera C, Zennou V, Charneau P, Mallet J. Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol Cell Neurosci 2002; 19: 389-401.
76. Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU, Eto Y. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res 2003; 74: 266-277.
77. Sakurai K, Iizuka S, Shen JS, et al. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Gene Ther 2004; 11: 1475-1481.
78. Robinson AJ, Zhao G, Rathjen J, et al. Embryonic stem cellderived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain. Cell Transplant 2010; 191(8): 985-998.
79. Zhao G, Karageorgos L, Hutchinson RG, Hopwood JJ, Hemsley K. Genetic manipulation of murine embryonic stem cells with enhanced green fluorescence protein and sulfatase-modifying factor I genes. Cytotherapy 2010; 12: 400-407.
80. Berkin A, Szarek WA, Kisilevsky R. Synthesis of 4-deoxy-4-fluoro analogues of 2-acetimido-2-deoxy-D-galactose and their effects on cellular glycosaminoglycan biosynthesis. Carb Res 2000; 326: 250-263.
81. Roberts ALK, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S. Inhibition of glycosaminoglycan synthesis using Rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Ped Res 2006; 60: 309-314.
82. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, et al. Genistein- mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006; 14: 846-852.
83. Malinowska M, Wilkinson FL, Bennett W, et al. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 2009; 98: 235-242.
84. Roberts ALK, Rees MH, Klebe S, Fletcher JM, Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Gen Met 2007; 92: 115-121.
85. Roberts ALK, Fletcher JM, Moore L, Byers S. Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol Gen Met 2010; 101: 208-213.
86. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson DS, Byers S. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet 2010; 18; 194-199.
87. Dziedzic D, Wegrzyn G, Jakóbkiewicz-Banecka J. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet 2010; 18: 200-205.
88. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825.
89. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008; 105: 10238-10243.
90. Song E, Lee SK, Wang J, et al. RNA interference targeting Fast protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
91. Marshall J, McEachern KA, Chuang WL, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 2010; 33: 281-289.